Alto Neuroscience CEO, Amit Etkin M.D., Ph.D., to Participate in National Academies of Sciences, Engineering and Medicine Workshop on Multimodal Biomarkers for Central Nervous System Disorders

LOS ALTOS, Calif., March 7, 2023 – Alto Neuroscience today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, will participate in the National Academies of Sciences, Engineering and Medicine Workshop on Multimodal Biomarkers for Central Nervous System (CNS) Disorders: Development, Integration, and Clinical Utility, taking place March 13 - 14, 2023, in Washington, D.C.

Presentation details are as follows:

Session Title: Session 3: Standardization and Methodological Considerations
Speakers: Hao Zhu, Ph.D., Food and Drug Administration; Amit Etkin, M.D., Ph.D., Alto Neuroscience; Martha Shenton, Ph.D., Harvard University; Visar Berish, Ph.D., Aural Analytics
Date: Tuesday, March 14, 2023
Time: 12:30 – 2 p.m. ET

This 1.5-day public workshop will bring together experts and key stakeholders from academia, industry, government, philanthropic foundations, and disease-focused non-profit organizations to examine the potential to develop multimodal biomarkers for CNS disorders through the integration of different biomarkers while exploring steps toward this goal. To learn more and register for the event, please visit the event website.

About Alto Neuroscience
Alto Neuroscience is pioneering precision psychiatry by developing targeted medicines to help patients get better faster. Differences in individuals' biology impact how they respond to treatment. Alto's Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, behavioral task performance, wearable data, genetics, and other factors to match each patient with the right Alto drug. The company's work in identifying and categorizing core domains of mental function (cognition, emotion, and sleep processes) has resulted in a multiple modality approach that supports robust drug-response predictions. Alto's clinical-stage pipeline includes first- or best-in-class novel drug candidates in depression, PTSD, and other mental health conditions, resulting in the broadest and most-advanced precision psychiatry effort. For more information, visit https://www.altoneuroscience.com or follow us on Twitter.

Investor Contact
Nick Smith
corporate@altoneuroscience.com

Media Contact
Jordann Merkert
media@altoneuroscience.com